These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 9605599)

  • 1. Benefits of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands.
    Morisco C; Lembo G; Sarno D; Argenziano L; Fratta L; Rozza F; Trimarco B
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S27-33. PubMed ID: 9605599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
    Lüscher TF; Wenzel RR; Moreau P; Takase H
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE-inhibitors in coronary artery disease?
    Vogt M; Motz W; Strauer BE
    Basic Res Cardiol; 1993; 88 Suppl 1():43-64. PubMed ID: 8357335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of ACE inhibitors and calcium antagonists: a logical approach.
    Ruschitzka FT; Noll G; Lüscher TF
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S5-16. PubMed ID: 9605596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin converting enzyme inhibitor-calcium antagonist combination: an alliance for cardioprotection?
    Ferrari R
    J Hypertens Suppl; 1997 Mar; 15(2):S109-17. PubMed ID: 9218207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of cardiac function, geometry, energetics and coronary reserve in hypertensive heart disease.
    Strauer BE
    Nephron; 1987; 47 Suppl 1():76-86. PubMed ID: 2962004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.
    Pepine CJ; Handberg-Thurmond E; Marks RG; Conlon M; Cooper-DeHoff R; Volkers P; Zellig P
    J Am Coll Cardiol; 1998 Nov; 32(5):1228-37. PubMed ID: 9809930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of circadian rhythms on drug response in hypertension and coronary heart disease--from mice and man.
    Lemmer B
    Pharmacol Ther; 2006 Sep; 111(3):629-51. PubMed ID: 16480770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combination therapy on the heart.
    Messerli FH; Michalewicz L
    J Hum Hypertens; 1997 Jan; 11(1):29-33. PubMed ID: 9111154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction.
    Beckwith C; Munger MA
    Ann Pharmacother; 1993 Jun; 27(6):755-66. PubMed ID: 8329800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?
    Remme WJ
    Drugs; 1997; 54 Suppl 5():59-70. PubMed ID: 9429846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary reserve in experimental myocardial hypertrophy.
    Gosse P; Clementy J
    Eur Heart J; 1995 Aug; 16 Suppl I():22-5. PubMed ID: 8829953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
    Schmieder RE; Martus P; Klingbeil A
    JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.